Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leflunomide + rituximab
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of leflunomide (a disease-modifying antirheumatic drug) and rituximab (a monoclonal antibody targeting CD20 on B cells). This combination is used primarily for treating rheumatoid arthritis in patients who are intolerant to methotrexate or have inadequate response to methotrexate alone. Leflunomide inhibits dihydroorotate dehydrogenase, preventing de novo pyrimidine synthesis needed for lymphocyte proliferation, while rituximab eliminates B cells through antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
02
Targets
CD20 (B-lymphocyte antigen CD20)DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)Tyrosine kinase
Beyond the preview
Go deeper on leflunomide + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leflunomide + rituximab.